Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from HUTCHMED (China) Limited ( (HK:0013) ).
HUTCHMED (China) Limited has announced an Extraordinary General Meeting (EGM) to be held on March 31, 2025, to approve the proposed disposal of its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. This strategic move is expected to impact the company’s operations and industry positioning, potentially affecting stakeholders by altering its investment portfolio and focus.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 2.98%
Average Trading Volume: 49,837
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.15B
For a thorough assessment of 0013 stock, go to TipRanks’ Stock Analysis page.